Mereo BioPharma Group plc SEC filings MREO
Mereo BioPharma Group plc has 439 filings in SEC EDGAR's recent list, going back to Dec 1, 2017. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 19, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 9, 2026 | Apr 8, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 27, 2026 | Mar 27, 2026 |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 13, 2025 |
| DEF 14A | Proxy statement | Apr 24, 2024 | May 23, 2024 |
Showing 4 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MREO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1719714
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.